

#4
COPY OF PAPERS
ORIGINALLY FILED

Secretary
Box 1/Seq.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(MBHB00-830-A; RPI 600/005)

In re the Application of:)

Vargeese, et al.)

Serial No.: 09/887,182)

Filed: June 22, 2001)

For: METHOD FOR THE CHEMICAL)
SYNTHESIS OF OLIGONUCLEOTIDES)

Group Art Unit: Unassigned

Examiner: Unassigned.

TRANSMITTAL LETTER

Box Missing Parts
Commissioner of Patents
Washington, D.C. 20231

Sir:

In regard to the above-identified application:

1. We are transmitting herewith the attached
 - a. Response to Notice to File Missing Parts of Application;
 - b. Copy of Notice to File Missing Parts of Application;
 - c. Executed copy of Oath or Declaration;
 - d. Statement of Compliance of the substitute Sequence Listing under 37 CFR §§ 1.821 – 1.825;
 - e. Computer readable form (CRF) of the substitute Sequence Listing (1 diskette) under 37 CFR § 1.825(b);
 - f. Paper copy of Sequence Listing;
 - g. Return Receipt Postcard
2. With respect to additional fees:
 - a. No additional fee is required.
 - X b. Please debit Deposit Account No. 13-2490 \$65.00 pursuant to 37 C.F.R. §1.17(a).
3. Please charge any deficiency in the amount due, or credit any overpayment, to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.

DISK TO STIC


DATE:

McDONNELL BOEHNEN HULBERT & BERGHOFF
300 South Wacker Drive
Chicago, Illinois 60606
(312) 913-0001



CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as "First Class Mail" in an envelope addressed to: Asst. Commissioner for Patents, Box Missing Parts, Washington, D.C. 20231, on December 21, 2001.

By:


Christopher P. Singer
Reg No. 48,701

**COPY OF PAPERS
ORIGINALLY FILED**



IN THE SEQUENCE LISTING:

Please replace the previously filed sequence listing with the substitute sequence listing submitted herewith. The sequence listing has been amended in order to comply with the requirements of 37 CFR §§ 1.821-1.825. No part of the sequence listing goes beyond the disclosure found in the application as originally filed.

Remarks

**COPY OF PAPERS
ORIGINALLY FILED**

Sequence Listing

Applicants have attached a substitute written paper copy and a substitute computer readable copy of the sequence listing. As required by 37 C.F.R. 1.821(e), 1.821(f), 1.821(g), 1.825(b), and/or 1.825(d), the information recorded in computer readable form is identical to the written form and includes no new matter. A separate statement of compliance is included herewith.

The substitute sequence listing filed herewith has been amended from the previously filed sequence listing, mailed June 22, 2001. The sequence listing filed June 22, 2001 contained several typographical errors in SEQ ID NO: 1, and has been amended accordingly. Support for the amendments to the sequence can be found in the specification as filed, for example, at page 55, line 16; page 57, line 7; and page 58, line 22. This amendment does not constitute new matter.

Further, the raw sequence listing error report indicated that the "Artificial Sequence" description at <223> was insufficient. The Applicants have elected to describe the sequence as "Synthetic Enzymatic Nucleic Acid" and have amended the sequence listing accordingly. This amendment is fully supported by the application as filed, for example, at page 55, line 16; page 57, line 7; and page 58, line 22.

Lastly, the error report also objected to the disclosure of an abasic moiety found in the sequence as "n", as "n" is reserved for nucleic acid groups only. The Applicants have elected to remove the "n" and insert a miscellaneous feature describing a modification to the 3'-end nucleic

acid of the sequence, in order to clarify the sequence and conform completely with 37 CFR §§ 1.821-1.825.

If the Examiner has any questions regarding this Response, the Examiner is invited to call the undersigned.

Respectfully submitted,
McDonnell, Boehnen, Hulbert & Berghoff

Dated: 12/21/2001

By: 

Christopher P. Singer
Reg. No. 48,701



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(MBHB00-830-A; RPI 600/005)

In re the Application of:)
)
Vargeese, et al.)
)
Serial No.: 09/887,182)
)
Filed: June 22, 2001)
)
For: METHOD FOR THE CHEMICAL)
SYNTHESIS OF OLIGONUCLEOTIDES)

Group Art Unit: Unassigned
Examiner: Unassigned.

#4

COPY OF PAPERS
ORIGINALLY FILED

Commissioner for Patents
Washington, D.C. 20231


STATEMENT UNDER 37 CFR §§ 1.821(f) and 1.825(b)

Dear Sir:

The information recorded in the computer readable copy of the SEQUENCE LISTING submitted herewith is identical to the information in the printed copy of the SEQUENCE LISTING submitted herewith, and includes no new matter. The copies are submitted in accordance with 37 CFR §§ 1.821-1.825.

Date: December 21, 2001


Respectfully submitted,


Christopher P. Singer
Registration No. 48,701

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, IL 60606
Telephone: 312-913-0001
Facsimile: 312-913-0002



UNITED STATES PATENT AND TRADEMARK OFFICE



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/887,182	06/22/2001	Chandra Vargeese	MBHB00,830-A (600/005)

CONFIRMATION NO. 8596

20306
MCDONNELL BOEHNEN HULBERT & BERGHOFF
300 SOUTH WACKER DRIVE
SUITE 3200
CHICAGO, IL 60606

FORMALITIES LETTER



OC00000006991403

**COPY OF PAPERS
ORIGINALLY FILED**

Date Mailed: 10/29/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted


An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(l) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 65.**
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- **For Rules Interpretation, call (703) 308-4216**
- **To Purchase PatentIn Software, call (703) 306-2600**
- **For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov**

*A copy of this notice **MUST** be returned with the reply.*

A handwritten signature in black ink, consisting of stylized, overlapping loops, positioned above a horizontal line.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 3 - OFFICE COPY